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Clinical Trials
William F. Rosenberger and Oleksandr Sverdlov
Abstract. There has been a split in the statistics community about the
need for taking covariates into account in the design phase of a clinical
trial. There are many advocates of using stratification and covariate-
adaptive randomization to promote balance on certain known covari-
ates. However, balance does not always promote efficiency or ensure
more patients are assigned to the better treatment. We describe these
procedures, including model-based procedures, for incorporating covari-
ates into the design of clinical trials, and give examples where balance,
efficiency and ethical considerations may be in conflict. We advocate a
new class of procedures, covariate-adjusted response-adaptive (CARA)
randomization procedures that attempt to optimize both efficiency and
ethical considerations, while maintaining randomization. We review all
these procedures, present a few new simulation studies, and conclude
with our philosophy.
Key words and phrases: Balance, covariate-adaptive randomization,
covariate-adjusted response-adaptive randomization, efficiency, ethics.
1. INTRODUCTION
Clinical trials are often considered the “gold stan-
dard” in convincing the medical community that a
therapy is beneficial in practice. However, not all
clinical trials have been universally convincing. Tri-
als that have inadequate power, or incorrect assump-
tions made in planning for power, imbalances on
important baseline covariates directly related to pa-
tient outcomes, or heterogeneity in the patient pop-
ulation, have contributed to a lack of scientific con-
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sensus. Hence, it is generally recognized that the
planning and design stage of the clinical trial is of
great importance. While the implementation of the
clinical trial can often take years, incorrect assump-
tions and forgotten factors in the sometimes rushed
design phase can cause controversy following a trial.
For example, take the trial of erythropoietin in main-
taining normal hemoglobin concentrations in patients
with metastatic breast cancer (Leyland-Jones, 2003).
This massive scientific effort involved 139 clinical
sites and 939 patients. The study was terminated
early because of an increase in mortality in the ery-
thropoietin group. The principal investigator
explains:
. . . drawing definitive conclusions has been
difficult because the study was not de-
signed to prospectively collect data on many
potential prognostic survival factors that
might have affected the study outcome. . . .
The results of this trial must be inter-
preted with caution in light of the poten-
tial for an imbalance of risk factors be-
tween treatment groups. . . . The randomi-
sation design of the study may not have
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fully protected against imbalances because
the stratification was only done for one
parameter, . . . and was not done at each
participating centre. . . . It is extremely un-
fortunate that problems in design. . . have
complicated the interpretation of this study.
Given the number of design issues uncov-
ered in the post hoc analysis, the results
cannot be considered conclusive.
An accompanying commentary calls this article
“alarmist,” thus illustrating the scientific conundrum
that covariates present in clinical trials. There is no
agreement in the statistical community about how
to deal with potentially important baseline covari-
ates in the design phase of the trial. Traditionally,
prestratification has been used on a small number
of very important covariates, followed by stratified
analyses. But what if the investigator feels there are
many covariates that are important—too many, in
fact, to feasibly use prestratification?
The very act of randomization tends to mitigate
the probability that important covariates will be dis-
tributed differently among treatment groups. This
property is what distinguishes randomized clinical
trials from observational studies. However, this is a
large sample property, and every clinical trialist is
aware of randomized trials that resulted in signif-
icant baseline covariate imbalances. Grizzle (1982)
distinguished two factions of the statistical commu-
nity, the “splitters” and the “lumpers.” The splitters
recommend incorporating important covariates into
randomization, thus ensuring balance over these co-
variates at the design stage. The lumpers suggest
ignoring covariates in the design and use simple ran-
domization to allocate subjects to different treat-
ment groups, and adjust for covariates at the analy-
sis stage. As Nathan Mantel once pointed out (Gail,
1992):
. . . After looking at a data set, I might see
that in one group there are an unusually
large number of males. I would point out
to the investigators that even though they
had randomized the individuals to treat-
ments, or claimed that they had, I could
still see that there was something unbal-
anced. And the response I would get was
“Well, we randomized and therefore we
don’t have to bother about it.” But that
isn’t true. So, as long as the imbalance
is an important factor you should take it
into account. Even though it is a designed
experiment, in working with humans, you
cannot count on just the fact that you ran-
domized.
Today, many statisticians would argue that the only
legitimate adjusted analyses are for prespecified im-
portant covariates planned for in the analysis ac-
cording to protocol, and that these adjustments should
be done whether or not the distributions are imbal-
anced (e.g., Permutt, 2000). In addition, these co-
variates should be accounted for in the design of the
trial, usually by prestratification, if possible.
The three-stage philosophy of prestratifying on
important known covariates, followed by a stratified
analysis, and allowing for randomization to “take
care of” the other less important (or unknown) co-
variates, has become a general standard in clinical
trials. This method breaks down, however, when
there are a large number of important covariates.
This has led to the introduction of covariate-adaptive
randomization procedures, sometimes referred to as
minimization procedures or dynamic allocation.1 Some
of these “covariate-adaptive” procedures (the term
we will use) that have been proposed have been ran-
domized, and others not.
There is no consensus in either the statistics world
or the clinical trials world as to whether and when
these covariate-adaptive procedures should be used,
although they are gaining in popularity and are now
used frequently. Recently clinical trialists using these
procedures have grown concerned that regulatory
agencies have expressed skepticism and caution about
the use of these techniques. In Europe, The Com-
mittee on Proprietary Medicinal Products (CPMP)
Points to Consider Document (see Grouin, Day and
Lewis, 2004) states:
Dynamic allocation is strongly discourag-
ed. . . . Without adequate and appropriate
supporting/sensitivity analysis, an appli-
cation is unlikely to be successful.
This document has led to much controversy. In a
commentary, Buyse and McEntegart (2004) state:
1Or sometimes, unfortunately, as just adaptive designs,
which could refer to any number of statistical methods hav-
ing nothing to do with covariates, including response-adaptive
randomization, sequential monitoring, and flexible interim de-
cisions.
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In our view, the CPMP’s position is un-
fair, unfounded, and unwise. . . . It favors
the use of randomization methods that ex-
pose trialists and the medical community
to the risk of accidental bias, when the risk
could have been limited through the use
of balancing methods that are especially
valuable. . . . If there were any controversy
over the use of minimization, it would be
expected of an independent agency to weigh
all the scientific arguments, for and against
minimization, before castigating the use
of a method that has long been adopted
in the clinical community.
In a letter to the editor, Day, Grouin and Lewis
(2005) respond that
. . . the scientific community is not of one
mind regarding the use of covariate-adaptive
randomization procedures. . . . Rosenberger
and Lachin cautiously state that “very lit-
tle is known about its theoretical proper-
ties.” This is a substantial point. The di-
rect theoretical link between randomiza-
tion and methods of statistical analysis
has provided a solid foundation for reli-
able conclusions from clinical trial work
for many years.
It is in the context of this controversy that this
paper is written. The intention of this paper is to
explore the role of covariates in the design of clini-
cal trials, and to examine the burgeoning folklore in
this area among practicing clinical trialists. Just be-
cause a technique is widely used does not mean that
it is valuable. And just because there is little theo-
retical evidence validating a method does not mean
it is not valid. The nonspecificity of the language
in these opinion pieces is becoming troubling: what
is meant by the terms “minimization,” “dynamic,”
“adaptive”? Many procedures to mitigate covariate
imbalances have been proposed. Are they all equally
effective or equally inappropriate? We add to the
controversy by discussing the often competing crite-
ria of balance, efficiency and ethical considerations.
We demonstrate by example that clinical trials that
balance on known covariates may not always lead
to the most efficient or the most ethically attractive
design, and vice versa.
This paper serves as both a review and a summary
of some of our thoughts on the matter; in particu-
lar, we advocate a new class of procedures called
covariate-adjusted response-adaptive (CARA) ran-
domization procedures (e.g., Hu and Rosenberger,
2006). The outline of the paper is as follows. In
Section 2, we review the most popular covariate-
adaptive randomization procedures. In Section 3,
we describe randomization-based inference and its
relationship to clinical trials employing covariate-
adaptive randomization methods. In Section 4, we
discuss what is known from the literature about the
properties of the procedures in Section 2. In Sec-
tion 5, we describe the alternative model-based op-
timal design approach to the problem and describe
properties of these procedures in Section 6. In Sec-
tion 7, we discuss the relationship between balance,
efficiency and ethics, and describe philosophical ar-
guments about whether balance or efficiency is a
more important criterion. We demonstrate by ex-
ample that balance does not necessarily imply ef-
ficiency and vice versa, and demonstrate that bal-
anced and efficient designs do not necessarily place
more patients on the better treatment. In Section 8,
we describe CARA randomization procedures and
their properties. In Section 9, we report the results of
a simulation study comparing different CARA and
covariate-adaptive randomization procedures for a
binary response trial with covariates. Finally, we
give a summary of our own opinions in Section 10.
2. COVARIATE-ADAPTIVE RANDOMIZATION
Following Rosenberger and Lachin (2002), a ran-
domization sequence for a two-treatment clinical trial
of n patients is a random vector Tn = (T1, . . . , Tn)
′,
where Tj = 1 if the jth patient is assigned to treat-
ment 1 and Tj = −1 if the patient is assigned to
treatment 2. A restricted randomization procedure is
given by φj+1 =Pr(Tj+1 = 1|Tj), that is, the proba-
bility that the (j+1)th patient is assigned to treat-
ment 1, given the previous j assignments. When the
randomization sequence is dependent on a patient’s
covariate vector Z, we have covariate-adaptive ran-
domization. In particular, the randomization pro-
cedure can then be described by φj+1 = Pr(Tj+1 =
1|Tj ,Z1, . . . ,Zj+1), noting that the current patient
is randomized based on the history of previous treat-
ment assignments, the covariate vectors of past pa-
tients and the current patient’s covariate vector.
The goal of covariate-adaptive randomization is to
adaptively balance the covariate profiles of patients
randomized to treatments 1 and 2. Most techniques
for doing so have focused on minimizing the dif-
ferences of numbers on treatments 1 and 2 across
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strata, often marginally. Note that covariate-adaptive
randomization induces a complex covariance struc-
ture, given by Var(Tn|Z1 = z1, . . . ,Zn = zn) =Σn,z.
For a small set of known discrete covariates, pre-
stratification is the most effective method for forcing
balance with respect to those covariates across the
treatment groups. The technique of prestratification
uses a separate restricted randomization procedure
within each stratum. For notational purposes, if dis-
crete covariate Zi, i = 1, . . . ,K, has ki levels, then
restricted randomization is used within each of the∏K
i=1 ki strata.
The first covariate-adaptive randomization proce-
dures were proposed in the mid-1970s. Taves (1974)
proposed a deterministic method to allocate treat-
ments designed to minimize imbalances on impor-
tant covariates, called the minimization method.
Pocock and Simon (1975) and Wei (1978) described
generalizations of minimization to randomized clin-
ical trials. We will refer to this class of covariate-
adaptive randomization procedures asmarginal pro-
cedures, as they balance on covariates marginally,
within each of
∑K
i=1 ki levels of given covariates.
The general marginal procedure can be described
as follows for a two-treatment clinical trial. Let
Nijl(n) be the number of patients on treatment l in
level j of covariate Zi, i= 1, . . . ,K, j = 1, . . . , ki, l=
1,2, after n patients have been randomized. When
patient n + 1 is ready for randomization, the pa-
tient’s baseline covariate vector (Z1, . . . ,ZK) is ob-
served as (z1, . . . , zK). Then Di(n) = Nizi1(n) −
Nizi2(n) is computed for each i= 1, . . . ,K. A weighted
sum is then taken as D(n) =
∑K
i=1wiDi(n). The
measure D(n) is used to determine the treatment
of patient n + 1. If D(n) > 0 (< 0), then one de-
creases (increases) the probability of being assigned
to treatment 1 accordingly. Pocock and Simon (1975)
formulated a general rule using Efron’s (1971) biased
coin design as:
φn+1 =


1/2, if D(n) = 0,
p, if D(n)< 0,
1− p, if D(n)> 0.
When p = 1, we have Taves’s (1974) minimization
method, which is nonrandomized. Pocock and Si-
mon (1975) investigated p= 3/4.
Wei (1978) proposed a different marginal proce-
dure using urns. At the beginning of the trial, each of∑K
i=1 ki urns contain α1 balls of type 1 and α2 balls
of type 2. Let Uij denote the urn representing level
j of covariate zi, and let Yijk(n) be the number of
balls of type k in urn Uij after n patients have been
randomized. For each urn compute the imbalance
Dij(n) = (Yij1(n)−Yij2(n))/(Yij1(n)+Yij2(n)). Sup-
pose patient n+1 has covariate vector (z1, . . . , zK).
Select the urn such that Dizi(n) is maximized. Draw
a ball and replace. If it is a type k ball, assign
the patient to treatment k, and add αk balls of
type k with βk ≥ 0 balls of the opposite type to
each of the observed urns. The procedure is repeated
for each new eligible patient entering the trial. Wei
proved that if there is no interaction between the
covariates or between the treatment effect and co-
variates in a standard linear model, then marginal
balance is sufficient to achieve an unbiased estimate
of the treatment difference. Efron (1980) provided
a covariate-adaptive randomization procedure that
balances both marginally and within strata, but the
method applies only to two covariates.
There has been substantial controversy in the lit-
erature as to whether the introduction of random-
ization is necessary when covariate-adaptive proce-
dures are used. Randomization mitigates the proba-
bility of selection bias and accidental bias, and pro-
vides a basis for inference (e.g., Rosenberger and
Lachin, 2002). Taves’s original paper did not advo-
cate randomization, and, in fact, he still supports
the view that randomization is unnecessary, writing
in a letter to the editor (Taves, 2004, page 180):
I hope that the day is not too far dis-
tant when we look back on the current
belief that randomization is essential to
good clinical trial design and realize that
it was. . . “credulous idolatry.”
Other authors have argued for using minimization
without the additional component of randomization.
Aickin (2001) argued that randomization is not needed
in covariate-adaptive procedures because the covari-
ates themselves are random, leading to randomness
in the treatment assignments. He also argued that
the usual selection bias argument for randomization
is irrelevant in double-masked clinical trials with a
central randomization unit.
Several authors, such as Zelen (1974), Nordle and
Brandmark (1977), Efron (1980), Signorini et al.
(1993) and Heritier, Gebski and Pillai (2005), pro-
posed covariate-adaptive randomization procedures
which achieve balanced allocation both within mar-
gins of the chosen factors and within strata. These
methods emphasize the importance of balancing over
interactions between factors when such exist.
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Raghavarao (1980) proposed an allocation proce-
dure based on distance functions. When the new
patient enters the trial, one computes dk, the Maha-
lanobis distance between the covariate profile of the
patient and the average of the patients already as-
signed to treatment k, where k = 1, . . . ,K. Then the
patient is assigned to treatment k with probability
pk ∝ dk.
3. RANDOMIZATION-BASED INFERENCE
One of the benefits of randomization is that it pro-
vides a basis for inference (see Chapter 7 of Rosen-
berger and Lachin, 2002). Despite this, assessment
of treatment effects in clinical trials is often con-
ducted using standard likelihood-based methods that
ignore the randomization procedure used. Letting
Y(n) = (Y1, . . . , Yn) be the response vector, T
(n)
n =
(T1, . . . , Tn) the treatment assignment vector and
Z(n) = (Z1, . . . ,Zn) the covariate vectors of patients
1, . . . , n, the likelihood can simply be written as
Ln = L(Y(n),T(n),Z(n); θ)
= L(Yn|Y(n−1),T(n),Zn; θ)
· L(Tn|Y(n−1),T(n−1),Z(n); θ)
· L(Zn|Y(n−1),T(n−1),Z(n−1))Ln−1.
As L(Yn|Y(n−1),T(n),Zn; θ) = L(Yn|Tn,Zn; θ), the
treatment assignments do not depend on θ, and the
covariates are considered i.i.d., we can reduce this
to the recursion
Ln ∝ L(Yn|Tn,Zn; θ)Ln−1
=
n∏
i=1
L(Yi|Ti,Zi; θ).
This is the standard regression equation under a
population model; that is, the randomization is an-
cillary to the likelihood. Thus, a proponent of the
likelihood principle would ignore the design in the
analysis, and proceed with tests standardly available
in SAS.
The alternative approach is to use a randomiza-
tion test, which is a simple nonparametric alter-
native. Under the null hypothesis of no treatment
effect, the responses should be a deterministic se-
quence unaffected by the treatment assigned. There-
fore, the distribution of the test statistic under the
null hypothesis is computed with reference to all
possible sequences of treatment assignments under
the randomization procedure.
Various authors have struggled with the appro-
priate way to perform randomization tests follow-
ing covariate-adaptive randomization. Pocock and
Simon (1975) initially suggested that the sequence
of covariate values and responses be treated as deter-
ministic, and the sequence of treatment assignments
be permuted for those specific covariate values. This
is the approach taken by most authors. Ebbutt et al.
(1997) presented an example where results differed
when the randomization test took into consideration
the sequencing of patient arrivals. Senn concluded
from this that the disease was changing in some way
through the course of the trial and thus there was a
time trend present (see the discussion of Atkinson,
1999).
4. WHAT WE KNOW ABOUT COVARIATE-
ADAPTIVE RANDOMIZATION PROCEDURES
Our knowledge of covariate-adaptive randomiza-
tion comes from (a) the original source papers; (b)
a vast number of simulation papers; (c) advocacy or
regulatory papers (for or against); and (d) review
papers. Very little theoretical work has been done
in this area, despite the proliferation of papers. The
original source papers are fairly uninformative about
theoretical properties of the procedures. In Pocock
and Simon (1975), for instance, there is a small dis-
cussion, not supported by theory, on the appropri-
ate selection of biasing probability p. There is no
discussion about the effect of the choice of weights
for the covariates; no discussion about the effect on
inference; no theoretical justification that the pro-
cedure even works as intended: Do covariate imbal-
ances (loosely defined) tend to zero? Does marginal
balance imply balance within strata or overall? Wei
(1978) devotes less than one page to a description of
his procedure; he does prove that marginal balance
implies balance within strata for a linear model with
no interactions. Taves (1974) is a nontechnical pa-
per with only intuitive justification of the method.
Simulation papers have been contradictory.
Klotz (1978) formalized the idea of finding an op-
timal value of biasing probability p as a constrained
maximization problem. Consider a trial withK treat-
ments and covariates. When patient n+ 1 is ready
to be randomized, one computes Dk, the measure
of overall covariate imbalance if the new patient is
assigned to treatment k = 1, . . . ,K. The goal is to
find the vector of randomization probabilities ρ =
(ρ1, . . . , ρK) which maximizes the entropy measure
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subject to the constraint on the expected imbal-
ance. Titterington (1983) built upon Klotz’s idea
and considered minimization of the quadratic dis-
tance between ρ and the vector of uniform probabil-
ities ρ0 = (1/K, . . . ,1/K) subject to the constraints
on the expected imbalance.
Aickin (2001) provides perhaps one of the few the-
oretical analyses of covariate-adaptive randomiza-
tion procedures. He gives a very short proof contra-
dicting some authors’ claims that covariate-adaptive
randomization can promote imbalances in unmea-
sured covariates. If X2 is an unmeasured covari-
ate, and covariate-adaptive randomization was used
to balance on covariate X1, then X2 can be de-
composed into its linear regression part, given by
L(X2|X1), and its linear regression residual X2 −
L(X2|X1). If X1 and X2 are correlated positively or
negatively, balancing onX1 will improve the balance
of L(X2|X1). Since the residual is not correlated
with the randomization procedure, X2 − L(X2|X1)
will balance as well as with restricted or complete
randomization. This is a formal justification of the
intuitive argument that Taves (1974) gave in his
original paper, an argument that Aickin (2001) says
is a “remarkably insightful observation.” Aickin also
uses causal inference modeling to show that, if the
unobserved errors correlated with the treatment as-
signments and known covariates are linearly related
to the known covariates, the treatment effect should
be unbiased.
There seems to be a troubling misconception in
the literature with regard to covariate-adaptive ran-
domization. For example, in an editorial in the British
Medical Journal (Treasure and MacRae, 1998) we
have the statement:
The theoretical validity of the method of
minimisation was shown by Smith. . . .
The quotation refers to Smith (1984b), which actu-
ally derives the asymptotic distribution of the ran-
domization test following a model-based optimal de-
sign approach favored by many authors. We shall
discuss this approach momentarily, but it is impor-
tant to point out that there is no justification, the-
oretical or otherwise, of minimization methods in
Smith’s paper.
In contrast to the dearth of publications exploring
covariate-adaptive randomization from a theoretical
perspective, a literature search revealed about 30
papers reporting results of simulation studies. Some
of these papers themselves are principally a review
of various other simulation papers. A glance at the
recent Society for Clinical Trials annual meeting ab-
stract guide revealed about 10 contributed talks re-
porting additional simulation results and their use
in clinical trials, indicating the continuing popular-
ity of these designs.
Papers dealing with the comparison of stratified
block designs with covariate-adaptive randomization
methods with respect to achieving balance on co-
variates include the original paper of Pocock and Si-
mon (1975), Therneau (1993), and review papers by
Kalish and Begg (1985) and Scott et al. (2002). The
general consensus is that covariate-adaptive random-
ization does improve balance for large numbers of
covariates.
Inference following covariate-adaptive randomiza-
tion has been explored by simulation in Birkett (1985),
using the t-test, Kalish and Begg (1987) using ran-
domization tests, and Frane (1998), using analysis
of covariance. Recent papers by Tu, Shalay and Pa-
ter (2000) and McEntegart (2003) cover a wide-
ranging number of questions. Tu et al. found that
minimization method is inferior to stratification in
reducing error rates, and argued that marginal bal-
ance is insufficient in the presence of interactions.
McEntegart concluded that there is little difference
in power between minimization method and strati-
fication. Hammerstrom (2003) performed some sim-
ulations and found that covariate-adaptive random-
ization does not significantly improve error rates,
but does little harm, and therefore is useful only for
cosmetic purposes.
We conclude this section by interjecting some rele-
vant questions. Does marginal balance improve power
and efficiency, or is it simply cosmetic? Is covariate-
adaptive randomization the proper approach to this
problem?
5. MODEL-BASED OPTIMAL
DESIGN APPROACHES
An alternate approach to balance is to find the
optimal design that minimizes the variance of the
treatment effect in the presence of covariates. This
approach is first found in Harville (1974), not in the
context of clinical trials, and in Begg and Iglewicz
(1980). The resulting designs are deterministic.
Atkinson (1982) adopted the approach and has
advocated it in a series of papers, and in the 1982 pa-
per, introduced randomization into the solution. In
order to keep consistency with the original paper, we
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summarize Atkinson’s approach for a general case of
K ≥ 2 treatments. Suppose K treatments are to be
compared, and responses follow the classical linear
regression model given by
E(Yi) = x
′
iβ, i= 1, . . . , n,
where the Yi’s are independent with Var(Y) = σ
2I
and xi is (K + q)× 1 vector which includes treat-
ment indicators and selected covariates of interest
(q is the number of covariates in the model). Let βˆ
be the least squares estimator of β. Then Var(βˆ) =
σ2(X′X)−1, whereX′X is the dispersion matrix from
n observations.
For the construction of optimal designs we wish
to find the n points of experimentation at which
some function is optimized (in our case we will be
finding the optimal sequence of n treatment assign-
ments). The dispersion matrix evaluated at these n
points is given by M(ξn) =X
′X/n, where ξn is the
n-point design. It is convenient, instead of thinking
of n points, to formulate the problem in terms of a
measure ξ (which in this case is a frequency distri-
bution) over a design region Ξ= {1, . . . ,K}.
Atkinson formulated the optimal design problem
as a design that minimizes, in some sense, the vari-
ance of A′βˆ, where A is a matrix of contrasts. One
possible criterion is Sibson’s (1974) DA-optimality
that maximizes
|A′M−1(ξ)A|−1.(1)
For any multivariable optimization problem, we
compute the directional derivative of the criterion.
In the case of the DA criterion in (1), we can derive
the Fre`chet derivative as
dA(x, ξ) = x
′M−1(ξ)A(A′M−1(ξ)A)−1A′M−1(ξ)x,
for x ∈ Ξ. By the classical Equivalence theorem of
Kiefer and Wolfowitz (1960), the optimal design ξ∗
that maximizes the criterion (1) then satisfies the
following equations:
sup
x∈Ξ
dA(x, ξ)≤ s ∀ξ ∈ Ξ
and
sup
x∈Ξ
dA(x, ξ
∗) = s.
Such a design is optimal for estimating linear con-
trasts of β. Assume n patients have already been al-
located, and the resulting n-point design is given by
ξn. Let the value of dA(x, ξ) for allocation of treat-
ment k be dA(k, ξ). Atkinson proposed a sequential
design which allocates the (n+ 1)th patient to the
treatment k = 1, . . . ,K for which dA(k, ξn) is a max-
imum, given the patient’s covariates. The resulting
design is deterministic.
In order to randomize the allocation, Atkinson
suggested biasing a coin with probabilities
ρk =
ψ(dA(k, ξn))∑K
k=1ψ(dA(k, ξn))
,(2)
where ψ(x) is any monotone increasing function,
and allocating to treatment k with the correspond-
ing probability. With two treatments, k = 1,2, we
have s= 1, A′ = (−1,1,0, . . . ,0), and the probabil-
ity of assigning treatment 1 is given by
φn+1 =
ψ(dA(1, ξn))
ψ(dA(1, ξn)) +ψ(dA(2, ξn))
.(3)
(We consider only the case of two treatments in this
paper.) Equation (3) gives a broad class of covariate-
adaptive randomization procedures. The choice of
function ψ has not been explored adequately. Atkin-
son (1982) suggested using ψ(x) = x; Ball, Smith
and Verdinelli (1993) suggested ψ(x) = (1 + x)1/γ
for a parameter γ ≥ 0, which is a compromise be-
tween randomness and efficiency.
Atkinson (1999, 2002) performed careful simula-
tion studies to compare the performance of several
covariate-adaptive randomization procedures for a
linear model with constant variance and trials up
to n = 200 patients. One criterion of interest was
loss, the expected amount of information lost due
to treatment and covariate imbalance. Another cri-
terion was selection bias, measuring the probability
of correctly guessing the next treatment assignment.
Atkinson observed that the deterministic procedure
based on the DA-optimality criterion has the small-
est value of loss, and Atkinson’s randomized proce-
dure (3) with ψ(x) = x increases the loss. He noted
that DA-optimal designs are insensitive to correla-
tion between the covariates, while complete random-
ization and minimization method increase the loss
when covariates are correlated.
6. WHAT WE KNOW ABOUT ATKINSON’S
CLASS OF PROCEDURES
Considerably more theoretical work has been done
on the class of procedures in (3) than for the covariate-
adaptive randomization procedures in Section 2. Most
of the work has been done in a classic paper by
Smith (1984a), although he dealt with a variant on
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the procedure in (3). It is instructive to convert to
his notation:
E(Yn) = αtn +
q∑
j=1
znjβj ,
where Yn and tn are the response and treatment
assignments of the nth patient, respectively, and
znj represent q covariates, and may include an in-
tercept. Let Tn be the treatment assignment vec-
tor and let Zn be the matrix of covariates. Then
Atkinson’s procedure in (3) can be formulated as
follows: assign tn+1 =±1 with probabilities propor-
tional to (±1−z′n+1(ZnZn)−1Zntn)2 (Smith, 1984b,
page 543). Smith (1984a) introduced a more general
class of allocation procedures given by
φn+1 = ψ(n
−1z′n+1Q
−1Z′ntn),(4)
where ψ is nonincreasing, twice continuously differ-
entiable function with bounded second derivative
satisfying ψ(x) + ψ(−x) = 1, and Q = E(znz′n) =
limn→∞ n
−1(Z′nZn). It is presumed that the {zn}
are independent, identically distributed random vec-
tors, Q is nonsingular and all third moments of zn
are finite. Note that the procedure (4) can be im-
plemented only if the distribution of covariates is
known in the beginning of the trial.
Smith suggested various forms of ψ, most leading
to a proportional biased coin raised to some power ρ.
In general, ρ=−2ψ′(0). Without covariates, Atkin-
son’s procedure in (2) leads to
φn+1 =
nρ2
nρ1 + n
ρ
2
,
where ρ = 2. Smith found the asymptotic variance
of the randomization test based on the simple treat-
ment effect, conditional on Zn. He did not do any
further analysis or draw conclusions except to sug-
gest that ρ should be selected by the investigator
to be as large as possible to balance the competing
goals of balance, accidental bias and selection bias.
7. BALANCE, EFFICIENCY OR ETHICS?
Clinical trials have multiple objectives. The prin-
cipal considerations are given in the schematic in
Figure 1. Balance across treatment groups is often
considered essential both for important covariates
and for treatment numbers themselves. Efficiency
is critical for demonstrating efficacy. Randomization
mitigates certain biases. Ethics is an essential com-
ponent in any human experimentation, and dictates
our treatment of patients in the trial. These consid-
erations are sometimes compatible, and sometimes
in conflict. In this section, we describe the interplay
among balance, efficiency and ethics in the context
of randomized clinical trials, and give some exam-
ples where they are in conflict.
In a normal error linear model with constant vari-
ance, numerical balance between treatments on the
margins of the covariates is equivalent to minimizing
the variance of the treatment effect. This is not true
for nonlinear models, such as logistic regression or
traditional models for survival analysis (Begg and
Kalish, 1984; Kalish and Harrington, 1988). As we
shall discuss further in the next section, balance does
not imply efficiency except in specialized cases. This
leaves open the question, is balance on covariates
important?
We have the conflict recorded in a fascinating in-
terchange among Atkinson, Stephen Senn and John
Whitehead (Atkinson, 1999). Whitehead argues:
I think that one criterion is really to re-
duce the probability of some large imbal-
ance rather than the variance of the esti-
mates. . . . And to make sure that these un-
convincing trials, because of the large im-
balance, happen with very low probabil-
ity, perhaps is more important. . . . I would
always be wanting to adjust for these vari-
ables. None the less, the message is sim-
pler if my preferred adjusted analysis is
similar to the simple message of the clin-
icians.
Senn gives the counterargument:
I think we should avoid pandering to these
foibles of physicians. . . . I think people worry
Fig. 1. Multiple objectives of a phase III clinical trial.
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far too much about imbalance from the in-
ferrential (sic) point of view. . . . The way I
usually describe it to physicians is as fol-
lows: if we have an unbalanced trial, you
can usually show them that by throwing
away some patients you can reduce it to a
perfectly balanced trial. So you can actu-
ally show that within it there is a perfectly
balanced trial. You can then say to them:
‘now, are you prepared to make an infer-
ence on this balanced subset within the
trial?’ and they nearly always say ‘yes.’
And then I say to them, ‘well how can a
little bit more information be worse than
having just this balance trial within it?’
We thus encounter once again deep philosophical
differences and the ingrained culture of clinical tri-
alists. Fortunately, balance and efficiency are equiv-
alent in homoscedastic linear models. Thus, strati-
fied randomization and covariate-adaptive random-
ization procedures (such as Pocock and Simon’s
method) are valid to the degree in which they force
balance over covariates. Atkinson’s model-based ap-
proach is an alternative method that can incorpo-
rate treatment-by-covariate interactions and contin-
uous covariates. Atkinson’s class of procedures for
linear models has an advantage of being based on
formal optimality criteria as opposed to ad hoc mea-
sures of imbalance used in covariate-adaptive ran-
domization procedures. On the other hand, balanced
designs may not be most efficient in the case of non-
linear and heteroscedastic models. We agree with
Senn that cosmetic balance, while psychologically
reassuring, should not be the goal if power or effi-
ciency is lost in the process of forcing balance.
First, let us illustrate that balanced allocation can
be less efficient and less ethically appealing than
unbalanced allocation in some instances, and that
there may exist unbalanced designs which outper-
form balanced designs in terms of compound ob-
jectives of efficiency and ethics. Consider a binary
response trial of size n comparing two treatments A
and B, and suppose there is an important binary
covariate Z, say gender (Z = 0 if a patient is male,
and Z = 1 if female), such that there are n0 males
and n1 females in the trial. Also assume that success
probabilities for treatment k are pk0 for males and
pk1 for females, where k = A,B. Let qkj = 1 − pkj ,
j = 0,1. For the time being we will assume that the
true success probabilities are known. One measure
of the treatment effect for binary responses is the
log-odds ratio, which can be expressed as
logOR(Z = j) = log
pAj/qAj
pBj/qBj
, j = 0,1.(5)
An experimental design question is to determine
allocation proportions piAj and piBj in stratum j
for treatments A and B, respectively, where j = 0
(male) or j = 1 (female). Let us consider the follow-
ing three allocation rules:
Rule 1: Balanced treatment assignments in the two
strata, given by
piAj = piBj = 1/2, j = 0,1;
Rule 2: Neyman allocation maximizing the power
of the stratified asymptotic test of the log-odds ra-
tio:
Tj =
log ÔR(Z = j)√
v̂ar(log ÔR(Z = j))
, j = 0,1.
The allocation proportion is given by
pi∗Aj =
1/
√
pAjqAj
1/
√
pAjqAj +1/
√
pBjqBj
, j = 0,1;
Rule 3: the analog of Rosenberger et al.’s (2001)
optimal allocation minimizing the expected number
of treatment failures in the trial subject to the fixed
variance of the log-odds ratio. This is given by
pi∗∗Aj =
1/
√
pAjq2Aj
1/
√
pAjq
2
Aj +1/
√
pBjq
2
Bj
, j = 0,1.
Note that unlike Rule 1, Rules 2 and 3 depend
on success probabilities in the two strata, and are
unbalanced, in general. Consider a case when n0 =
n1 = 100 and let (pA0, pB0) = (0.95,0.7) and (pA1,
pB1) = (0.7,0.95). This represents a case when one
of the treatments is highly successful, there is sig-
nificant treatment difference between A and B, and
there is treatment-by-covariate interaction (treat-
ment A is more successful for males and is less suc-
cessful for females). Then allocation proportions for
treatment A in the two strata are piA0 = 0.68 and
piA1 = 0.32 for Rule 2, and piA0 = 0.84 and piA1 =
0.16 for Rule 3.
All three rules are very similar in terms of ef-
ficiency, as measured by the asymptotic variances
of stratum-specific estimates of the log-odds ratio.
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However, Rules 2 and 3 provide extra ethical sav-
ings. For the sample size considered, Rule 3 is ex-
pected to have 16 fewer failures than the balanced
design. At the same time, Rule 2, whose primary
purpose is optimizing efficiency, is expected to have
8 fewer failures than the balanced allocation. There-
fore, in addition to maximizing efficiency, Rule 2
provides additional ethical savings, and is certainly
far more attractive than balanced allocation.
So far we have compared different target alloca-
tions for “fixed” designs, that is, for a given num-
ber of patients in each treatment group and known
model parameters. In practice, true success proba-
bilities are not available at the trial onset, which
precludes direct implementation of Rules 2 and 3.
Since clinical trials are sequential in nature, one
can use accruing responses to estimate the parame-
ters, and then cast a randomization procedure which
asymptotically achieves the desired allocation. To
study operating characteristics of response-adaptive
randomization procedures targeting Neyman alloca-
tion (Rule 2) and optimal allocation (Rule 3) we
ran a simulation study in R using 10,000 replica-
tions (results are available from the second author
upon request). In the simulations we assumed that
two strata (male and female) are equally likely. For
Rules 2 and 3, the doubly adaptive biased coin de-
sign (DBCD) procedure of Hu and Zhang (2004) was
used within each stratum to sequentially allocate pa-
tients to treatment groups. In addition, balanced al-
location was implemented using stratified permuted
block design (PBD) with block size m = 8. We as-
sumed that responses are immediate, and compared
the procedures with respect to power of the strat-
ified asymptotic test of the log-odds ratio for test-
ing the null hypothesis H0: (pA0 = pB0) and (pA1 =
pB1) versus HA: not H0 using significance level α=
0.05, and the expected number of treatment fail-
ures. We considered several experimental scenarios
for success probabilities (pAj, pBj), j = 0,1, includ-
ing the one described in the example above. To fa-
cilitate comparisons, the sample size for each ex-
perimental scenario was chosen such that the strati-
fied block design achieves approximately 80% power
of the test. In summary, response-adaptive random-
ization procedures worked as expected: for chosen
sample sizes they converged to the targeted alloca-
tions and preserved the nominal significance level.
Additionally, response-adaptive randomization pro-
cedures had similar average power to the PBD, but
on average they had fewer treatment failures. Ethi-
cal savings of response-adaptive designs were more
pronounced when one of the treatments had high
success probability (0.8–0.9) and treatment differ-
ences were large.
We would also like to emphasize that phase III
trials are pivotal studies, and one typically has an
idea about the success probabilities of the treat-
ments from early stage trials. If a particular allo-
cation is such that it leads to high power of the test,
and it is also skewed toward the better treatment,
then it makes sense to implement such a procedure.
The additional ethical savings can be prominent if
the ethical costs associated with trial outcomes are
high, such as deaths of trial participants.
8. CARA RANDOMIZATION
Hu and Rosenberger (2006) define a covariate-
adjusted response-adaptive (CARA) randomization
procedure as one for which randomization probabil-
ities for a current patient depend on the history of
previous patients’ treatment assignments, responses
and covariates, and the covariate vector of the cur-
rent patient, that is,
φj =Pr(Tj+1 = 1|Tj ,Yj,Z1, . . . ,Zj,Zj+1).(6)
There have been only few papers dealing with CARA
randomization, and it has become an area of active
research. CARA randomization is an extension of
response-adaptive randomization which deals with
adjustment for covariates. Response-adaptive ran-
domization has a rich history in the literature, and
the interested reader is referred to Section 1.2 of Hu
and Rosenberger (2006).
Bandyopadhyay and Biswas (2001) considered a
linear regression model for two treatments and co-
variates with an additive treatment effect and con-
stant variance. Suppose large values of response cor-
respond to a higher efficacy. Then the new patient
is randomized to treatment 1 with probability
φj+1 =Φ(dj/T ),(7)
where dj is the difference of covariate-adjusted treat-
ment means estimated from the first j patients, T
is a scaling constant and Φ is the standard nor-
mal c.d.f. Although procedure (7) depends on the
full history from j patients, it does not account for
covariates of the (j + 1)th patient, and it is not a
CARA procedure in the sense of (6). Also, this pro-
cedure depends on the choice of T , and small values
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of T can lead to severe treatment imbalances which
can lead to high power losses.
Atkinson and Biswas (2005a, 2005b) improved the
allocation rule of Bandyopadhyay and Biswas (2001)
by proposing CARA procedures that are based on a
weighted DA-optimal criterion combining both effi-
ciency and ethical considerations. They investigated
operating characteristics of the proposed designs
through simulation, but they did not derive asymp-
totic properties of the estimators and allocation pro-
portions. Without the asymptotic properties of the
estimators, it is difficult to assess the validity of sta-
tistical inferences following CARA designs.
A few papers describe CARA designs for binary
response trials. One of the first papers in this field is
by Rosenberger, Vidyashankar and Agarwal (2001).
They assumed that responses in treatment group
k =A,B follow the logistic regression model
logit(Pr(Yk = 1|Z= z)) = θ′kz,
where θk is a vector of model parameters for treat-
ment k. Let θˆjA and θˆjB be the maximum likelihood
estimators of model parameters computed from the
data from j patients. Then the (j + 1)th patient is
randomized to treatment A with probability
φj+1 = F ((θˆjA − θˆjB)′zj+1),
where F is the standard logistic c.d.f. Basically, each
patient is allocated according to the current value of
covariate-adjusted odds ratio comparing treatments
A and B. The authors compared their procedure
with complete randomization through simulations
assuming delayed responses. They showed that for
larger treatment effects both procedures have simi-
lar power, but at the same time the former results in
a smaller expected proportion of treatment failures.
Bandyopadhyay, Biswas and Bhattacharya (2007)
also dealt with binary responses. They proposed a
two-stage design for the logistic regression model.
At the first stage, 2m patients are randomized to
treatment A or B in a 1 : 1 ratio and accumulated
data are used to estimate model parameters. At the
second stage, each patient is randomized to treat-
ment A with a probability which depends on the
treatment effect estimated from the first stage and
the current patient’s covariate vector.
Theoretical properties of CARA procedures have
been developed in a recent paper by Zhang et al.
(2007). This paper proposed a general framework for
CARA randomization procedures for a very broad
class of models, including generalized linear models.
In the paper the authors proved strong consistency
and asymptotic normality of both maximum likeli-
hood estimators and allocation proportions. They
also examined the CARA design of Rosenberger,
Vidyashankar and Agarwal (2001) and provided
asymptotic properties of the procedure.
CARA procedures do not lend themselves to anal-
ysis via randomization-based inference. The theo-
retical validity of randomization tests is based on
conditioning on the outcome data as a set of suffi-
cient statistics, and then permuting the treatment
assignments. Under the null hypothesis of no treat-
ment difference, the observed outcome data should
be exchangeable, leading to a valid randomization p-
value (see Pesarin, 2001). However, under the CARA
procedure, the treatment assignments and outcomes
form the sufficient statistics, and conditioning on
both would leave nothing. One could perform a stan-
dard permutation test on the resulting data by intro-
ducing a “sham” equiprobable randomization, but
one would lose information about treatment efficacy.
Therefore, we rely on likelihood-based methods
to conduct inference following a CARA randomiza-
tion procedure, and Zhang et al. (2007) provide the
necessary asymptotic theory. For further discussion
of appropriate inference procedure following general
response-adaptive randomization procedures, refer
to Chapter 3 of Hu and Rosenberger (2006) and
Baldi Antognini and Giovagnoli (2005, 2006).
9. COMPARING DIFFERENT
RANDOMIZATION PROCEDURES WHICH
ACCOUNT FOR COVARIATES
In the following we used simulation to compare the
operating characteristics of several covariate-adaptive
randomization procedures and CARA procedures for
the logistic regression model. We used the covariate
structure considered in Rosenberger, Vidyashankar
and Agarwal (2001). Assume that responses for treat-
ment k satisfy the following logistic regression model:
logit(Pr(Yk = 1|z)) = αk +
3∑
j=1
βkjzj ,(8)
where αk is the treatment effect, and βkj is the ef-
fect due to the jth covariate in treatment group
k =A,B. The parameter of interest is the covariate-
adjusted treatment difference αA − αB . The
components of covariate vector z′ = (z1, z2, z3),
which represent gender, age and cholesterol level,
were assumed to be independently distributed as
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Bernoulli(1/2), Discrete Uniform[30,75] and
Normal(200,20). Note that model (8) allows for
treatment-by-covariate interactions, since covariate
effects βkj ’s are not the same across the treatments.
The operating characteristics of designs included
measures of balance, efficiency and ethics. For bal-
ance we considered the allocation proportion
NA(n)/n, and the allocation proportions within the
male category of covariate gender, NA0(n)/N0(n).
Also, we examined the Kolmogorov–Smirnov dis-
tance dKS(z2) between empirical distributions of co-
variate age in treatment groups A and B. The effi-
ciency of procedures was measured by the average
power of the asymptotic test of the log-odds ratio
evaluated at a given z0. The ethical aspect of a pro-
cedure was assessed by the total number of treat-
ment failures, F (n).
The sample size n was chosen in such a way that
complete randomization yields approximately 80%
or 90% power of the test of log-odds ratio under
a particular alternative. For each choice of n we
also estimated the significance level of the test un-
der the null hypotheses. We report the results for
three sets of parameter values given in Table 1. Un-
der the null hypothesis of no treatment difference
(Model 1), n= 200. When αA−αB =−1 (Model 2),
the choice of n= 200 yields 80% power for complete
randomization. When αA − αB =−1.25 (Model 3),
we let n= 160, which corresponds to 90% power for
complete randomization.
The first class of procedures are CARA designs.
For their implementation, we need to sequentially
estimate model parameters. In our simulations we
assumed that all responses are immediate after ran-
domization, although we can add a queuing struc-
ture to explore the effects of delayed response. For
CARA procedures, some data must accumulate so
that the logistic model is estimable. We used Pocock
and Simon’s method to allocate the first 2m0 pa-
tients to treatments A and B.
Table 1
Parameter values for the logistic regression model (8) used
in simulations
Model
1 2 3
Parameters A B A B A B
αk −1.652 −1.652 −1.402 −0.402 −1.652 −0.402
βk1 −0.810 −0.810 −0.810 0.173 −0.810 0.173
βk2 0.038 0.038 0.038 0.015 0.038 0.015
βk3 0.001 0.001 0.001 0.004 0.001 0.004
Suppose after n > 2m0 allocations the m.l.e. of
θk has been computed as θˆn,k. Then, for a sequen-
tial m.l.e. CARA procedure, the (n + 1)th patient
with covariate zn+1 is allocated to treatment A with
probability φn+1 = ρ(θˆn,A, θˆn,B,zn+1). We explored
four different choices of ρ:
1. Rosenberger, Vidyashankar and Agarwal’s (2001)
target:
ρ1 =
pA(z)/qA(z)
pA(z)/qA(z) + pB(z)/qB(z)
.
2. Covariate-adjusted version of Rosenberger et al.’s
(2001) allocation:
ρ2 =
√
pA(z)√
pA(z) +
√
pB(z)
.
3. Covariate-adjusted version of Neyman allocation:
ρ3 =
√
pB(z)qB(z)√
pB(z)qB(z) +
√
pA(z)qA(z)
.
4. Covariate-adjusted version of optimal allocation:
ρ4 =
√
pB(z)qB(z)√
pB(z)qB(z) +
√
pA(z)qA(z)
.
Here pk(z) = 1/(1 + exp(−θ′kz)) and qk(z) = 1 −
pk(z), k =A,B. We will refer to CARA procedures
with four described targets as CARA 1, CARA 2,
CARA 3 and CARA 4, respectively.
We also considered an analogue of Akinson and
Biswas’s (2005a) procedure for the binary response
case. It is worthwhile to describe this approach in
more detail. Consider model (8) and let θk = (αk,
β1k, β2k, β3k)
′. Suppose that a trial has nA patients
allocated to treatment A and nB = n− nA patients
allocated to treatment B. Then the information ma-
trix about θ = (θA,θB) based on n observations is
of the form
Mn = diag{Z′AWAZA,Z′BWBZB},
where Zk is the nk×p matrix of covariates for treat-
ment k, Wk is nk × nk diagonal matrix with ele-
ments pkqk. Here pk = pk(zi, θk) denote the success
probability on treatment k given zi and qk = 1− pk,
k = A,B. Suppose the (n+ 1)th patient enters the
trial. Then the directional derivative of the criterion
det(M) for treatment k given zn+1 is computed as
d(k,θn,zn+1) = z
′
n+1(Z
′
kWkZk)
−1zn+1pkqk.(9)
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Note that (9) depends on θk, which must be esti-
mated using the m.l.e. θˆn,k. The (n+ 1)th patient
is randomized to treatment A with probability
φn+1 =
fˆAd(A, θˆn,A,zn+1)∑B
k=A fˆkd(k, θˆn,k,zn+1)
,(10)
where fk is the desired proportion on treatment k.
We take fk = pk(z)/qk(z). The CARA procedure
(10) will be referred to as CARA 5.
The second class of allocation rules are covariate-
adaptive randomization procedures. For Pocock and
Simon’s (P–S) procedure, each component of zn+1 is
discretized into two levels, and the sum of marginal
imbalances within these levels is computed. The (n+
1)th patient is allocated with probability 3/4 to the
treatment which would minimize total covariate im-
balance. If imbalances for treatments A and B are
equal, then the patient is assigned to either treat-
ment with probability 1/2.
For the stratified permuted block design (SPBD),
the stratum of the current patient is determined
based on the observed combination of the patient’s
covariate profile. Within that stratum allocations
are made using permuted blocks of size m = 10. It
is possible that had some unfilled last blocks, and
thus perfect balance is not achieved. However, we
did not specifically examine this feature of SPBD.
We also report the results for complete randomiza-
tion (CRD).
The program performing the simulations was writ-
ten in R. For each procedure, a trial with n patients
was simulated 5000 times. To facilitate the compari-
son of the procedures, the n×4 matrix of covariates
Z was generated once and was held fixed for all sim-
ulations. For CARA procedures, the first 2m0 = 80
patients were randomized by Pocock and Simon’s
procedure with biasing probability p= 3/4. The re-
sponse probabilities of patients in treatment group
k =A,B were computed by multiplying the rows of
Z by the vector of model parameters and calculat-
ing the logistic c.d.f. F (x) = 1/(1 + exp(−x)) at the
computed values. The significance level of the test
was set α= 0.05, two-sided.
Table 2 shows the results under the null hypoth-
esis (Model 1). We see that all rules produce bal-
anced allocations. CARA 1, CARA 3 and CARA 4
procedures are slightly anticonservative, with a type
I error rate of 0.06, while the procedures CARA 2
and CARA 5 preserve the nominal significance level
of 0.05. Pocock and Simon’s procedure is the least
variable among the eight rules considered; the other
procedures are almost identical in terms of variabil-
ity of allocation proportions.
Tables 3 and 4 show the results for Models 2 and 3,
respectively. The conclusions are similar in the two
cases, and so we will focus on Model 2. Balanced de-
signs equalize the treatment assignments very well.
As expected, the stratified blocks and Pocock and
Simon’s procedure are less variable than complete
randomization. Similar conclusions about balancing
properties of the designs apply to balancing with
respect to the continuous covariates. The average
power is 90% for the stratified blocks and Pocock
and Simon’s procedure, and 89% for complete ran-
domization.
Let us now examine the performance of CARA
procedures. All CARA procedures are more variable
than the stratified blocks and Pocock and Simon’s
method, but a little less variable than complete ran-
domization. In addition, all CARA procedures do a
good job in terms of balancing the distributions of
the continuous covariates [estimated dKS(z2) = 0.13
(S.D. = 0.04) versus 0.14 (S.D. = 0.04) for complete
randomization]. CARA 2, CARA 3 and CARA 5
procedures are closest to the balanced design. The
simulated allocation proportions for treatment A
and the corresponding standard deviations are 0.48
(0.03) for CARA 2, and 0.48 (0.03) for CARA 3,
and 0.47 (0.03) for CARA 5 procedure. These three
CARA procedures have average power of 81%, same
as for stratified blocks and Pocock and Simon’s pro-
cedure, but at the same time they yield two fewer
failures than the balanced designs. CARA 4 proce-
dure has the power of 80% (same as for complete
randomization), but it has, on average, four fewer
failures than the balanced designs. CARA 1 proce-
dure is the most skewed: the simulated allocation
proportion for treatment A and the standard devia-
tion is 0.40 (0.04), and it results, on average, in six
fewer treatment failures than in the balanced design
case. On the other hand, it is less powerful than
balanced designs (the average power is 76%).
The overall conclusion is that CARA procedures
may be a good alternative to covariate-adaptive pro-
cedures targeting balanced allocations in the nonlin-
ear response case. Although incorporating responses
in randomization induces additional variability of al-
location proportions, which may potentially reduce
power, one can see from our simulations that such
an impact is not dramatic.
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Table 2
Simulation results for Model 1 with θA = θB and n= 200
Procedure NA(n)
n
(S.D.) NA0(n)
N0(n)
(S.D.) dKS(z2) (S.D.) Err. rate F (n) (S.D.)
CRD 0.50 (0.03) 0.50 (0.05) 0.12 (0.04) 0.05 90 (6)
SPBD 0.50 (0.03) 0.50 (0.04) 0.12 (0.03) 0.05 90 (6)
P–S 0.50 (0.00) 0.50 (0.01) 0.10 (0.03) 0.05 90 (6)
CARA 1 0.50 (0.03) 0.50 (0.04) 0.11 (0.03) 0.06 90 (6)
CARA 2 0.50 (0.03) 0.50 (0.04) 0.12 (0.03) 0.05 90 (6)
CARA 3 0.50 (0.02) 0.50 (0.04) 0.11 (0.03) 0.06 90 (6)
CARA 4 0.50 (0.02) 0.50 (0.04) 0.12 (0.03) 0.06 90 (6)
CARA 5 0.50 (0.02) 0.50 (0.04) 0.12 (0.04) 0.05 90 (6)
For CARA procedures, it is essential that the first
allocations to treatment groups are made by us-
ing some covariate-adaptive procedure or the strat-
ified block design, so that some data accrue and
one can estimate the unknown model parameters
with reasonable accuracy. From numerical experi-
ments we have found that at least 80 patients must
be randomized to treatment groups before m.l.e.’s
can be computed. Alternatively, one can check af-
ter each allocation the convergence of the iteratively
reweighted least squares algorithm for fitting the
logistic model, as Rosenberger, Vidyashankar and
Agarwal (2001) did. However, due to the slow con-
vergence of m.l.e.’s, we have found that it is bet-
ter, first, to achieve reasonable quality estimators by
using a covariate-adaptive randomization procedure
with good balancing properties (such as Pocock and
Simon’s method).
From our simulations one can see that there are
CARA procedures (such as CARA 4 procedure) which
have the same average power as complete random-
ization, but at the same time they result in three
Table 3
Simulation results for Model 2 with αA − αB =−1.0 and n= 200
Procedure NA(n)
n
(S.D.) NA0(n)
N0(n)
(S.D.) dKS(z2) (S.D.) Power F (n) (S.D.)
CRD 0.50 (0.04) 0.49 (0.05) 0.12 (0.04) 0.80 62 (6)
SPBD 0.50 (0.03) 0.50 (0.04) 0.12 (0.03) 0.81 62 (6)
P–S 0.50 (0.01) 0.50 (0.01) 0.10 (0.03) 0.81 62 (6)
CARA 1 0.40 (0.04) 0.45 (0.04) 0.12 (0.03) 0.76 56 (6)
CARA 2 0.48 (0.03) 0.49 (0.04) 0.12 (0.03) 0.81 60 (6)
CARA 3 0.48 (0.03) 0.49 (0.04) 0.12 (0.03) 0.81 60 (6)
CARA 4 0.45 (0.03) 0.48 (0.04) 0.12 (0.03) 0.80 58 (6)
CARA 5 0.47 (0.03) 0.50 (0.04) 0.12 (0.04) 0.81 60 (6)
Table 4
Simulation results for Model 3 with αA − αB =−1.25 and n= 160
Procedure NA(n)
n
(S.D.) NA0(n)
N0(n)
(S.D.) dKS(z2) (S.D.) Power F (n) (S.D.)
CRD 0.50 (0.04) 0.49 (0.05) 0.14 (0.04) 0.89 54 (6)
SPBD 0.50 (0.01) 0.50 (0.01) 0.12 (0.03) 0.89 54 (6)
P–S 0.50 (0.01) 0.50 (0.01) 0.11 (0.03) 0.90 54 (6)
CARA 1 0.39 (0.04) 0.43 (0.04) 0.13 (0.04) 0.86 50 (6)
CARA 2 0.47 (0.03) 0.48 (0.04) 0.13 (0.04) 0.90 53 (6)
CARA 3 0.48 (0.03) 0.48 (0.04) 0.13 (0.04) 0.90 54 (6)
CARA 4 0.44 (0.03) 0.45 (0.04) 0.13 (0.04) 0.89 51 (6)
CARA 5 0.47 (0.02) 0.50 (0.03) 0.12 (0.03) 0.91 53 (5)
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to four fewer failures than the balanced allocations.
Such extra ethical savings together with high power
for showing treatment efficacy can be a good reason
for using CARA procedures to design efficient and
more ethically attractive clinical trials.
10. DISCUSSION
The design of clinical trials has become a rote ex-
ercise, often driven by regulatory constraints. Boiler-
plate design sections in protocols and grant propos-
als are routinely presented to steering committees,
review committees, and data and safety monitoring
boards. It is not uncommon for the randomization
section of a protocol to state “double-blinded ran-
domization will be performed” with no further de-
tails. The fact that randomization is rarely if ever
used as a basis for inference means that the partic-
ular randomization sequence is not relevant in the
analysis, with the exception that stratified designs
typically lead to stratified tests. Balance among im-
portant baseline covariates is seen to be an essential
cosmetic component of the clinical trial, and many
statisticians recommend adjusting for imbalanced
covariates following the trial, even if such analyses
were not planned in the design phase. While effi-
ciency is usually gauged by a sample size formula,
the role that covariates play in efficiency, and the
idea that imbalances may sometimes lead to better
efficiency and more patients assigned to the supe-
rior treatment, are not generally considered in the
design phase of typical clinical trials.
In clinical trials with normally distributed out-
comes, where it is assumed that the variability of
the outcomes is similar across treatments, a bal-
anced design across treatments and covariates will
be the most efficient. In these cases, if there are sev-
eral important covariates, stratification can be em-
ployed successfully, and if there are many covariates
deemed of sufficient importance, covariate-adaptive
randomization can be used to create balanced, and
therefore efficient, designs.
However, as we have seen, these simple ideas break
down when there are heterogeneous variances, in-
cluding those found in commonly performed trials
with binary responses or survival responses. The
good news is that there are new randomization tech-
niques that can be incorporated in the design stage
that can lead to more efficient and more ethically
attractive clinical trials. These randomization tech-
niques are based on the optimal design of experi-
ments and also tend to place more patients on the
better treatment (Zhang et al., 2007). While more
work needs to be done on the properties of these
procedures, we agree with Senn’s comments that ef-
ficiency is much more important than cosmetic bal-
ance.
The design of clinical trials is as important as the
analysis of clinical trials. Ethical considerations and
efficiency should dictate the randomization proce-
dure used; careful selection of a good design can save
time, money, and in some cases patients’ lives. As
Hu and Rosenberger (2006) point out, modern infor-
mation technology has progressed to the point where
logistical difficulties of implementing more complex
randomization procedures are no longer an issue.
Careful design involves an understanding of both
the theoretical properties of a design in general, and
simulated properties under a variety of standard to
worst-case models. In some cases, the trade-offs in
patient benefits and efficiency are so modest com-
pared to the relative gravity of the outcome, that
standard balanced designs may be acceptable. How-
ever, when outcomes are grave, and balanced de-
signs may produce severe inefficiency or too many
patients assigned to the inferior treatment, careful
design is essential.
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